Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Suven Life Sciences has informed that the Board of Directors of the Company, at its meeting held today, August 6, 2026, has considered and approved Un-Audited Financial Results (Standalone and Consolidated) along with review reports of the Statutory Auditors for the quarter ended 30th June, 2026. The company has enclosed the following documents:- 1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026 enclosed as Annexure 1, 2. Limited Review Reports of Statutory Auditors of the Company enclosed as Annexure 2, 3. News Release of the Company enclosed as Annexure 3. Update on patents are available at: https://www.suven.com/Patentupdates.aspx. The Board Meeting commenced at 11:30 AM (IST) and concluded at 12:30 PM (IST).
The above information is a part of company’s filings submitted to BSE.
